IDO1 and neoplasm: IDO may inhibit intratumoral T-cell activity through the depletion of tryptophan in the tumor microenvironment or by recruiting immunosuppressive cells such as MDSCs and Tregs through activation of the aryl hydrocarbon receptor (AhR) by kynurenine [126].